Biovail Corporation Settles Cardizem Case with $22.2 Million Fine

Bookmark and Share

Reuters -- A U.S. unit of Canadian drugmaker Biovail Corp has pleaded guilty to conspiracy and kickback charges, ending a case over its Cardizem hypertension drug, the U.S. Justice Department said on Monday.

MORE ON THIS TOPIC